Market Access Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing BioSpaceCSL Vifor holds the marketing authorization for Tavneos in the U.K., where the drug is marketed as Avacopan Vifor.Immunology & InflammationRead full story pharminent September 2, 2026 (Last updated: September 2, 2026) BioSpace CSL Vifor holds the marketing authorization for Tavneos in the U.K., where the drug is marketed as Avacopan Vifor. Immunology & Inflammation Read full story Post navigation Previous: Ono Pharmaceutical joins forces with Aitia for drug discovery in neurologyNext: UK Suspends Amgen’s Tavneos for New Patients as a Data-Integrity Cascade Spreads Across Three Regulators Related Stories Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026 Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026